LipoCure Ltd. Information

Company Profile: LipoCure is start-up that focuses on development of nano-drugs based on liposomes. LipoCure utilizes the vast experience gained by Professor Yechezkel Barenholz, one of the major inventors and developers of the first FDA-approved nano-drug, Doxil®. Doxil is an anti-cancer drug considered as one of the gold standards of nano-drug delivery systems (DDS). The technological and biological knowledge gained during Doxil development has led to the development of anti-cancer nano-drugs with improved efficacy and reduced toxicity compared to Doxil, as well as to the development of anti-inflammatory nano-drugs. The LipoCure pipeline includes 3 projects close to clinical trials and other projects in pre-clinical stages. All the drugs developed by LipoCure share the principles of better control over pharmacokinetics and bio-distribution, passive targeting at the disease site and controlled drug release. All active pharmaceuticals used are generic. The overall superiority of LipoCure's novel drugs stems from the above advantages, enabling achieving an improved therapeutic index by improving efficacy and reducing toxicity. Technology Description: Utilizing the group's expertise in liposomes and nanotechnology, LipoCure has developed a pipeline of products: LC100 – Liposomal doxorubicin nano-drug with greater efficacy and reduced side effects, in particular, reduced hand and foot syndrome in comparison to current pegylated liposomal doxorubicin. LC200 – Long-circulating inflammation-targeted steroidal nano-liposomal drug with improved efficacy profile in pre-clinical animal models to be used as anti-inflammatory and anti-cancer drug. LC400 – ULALA (Ultra-Long-Acting Local Anesthetic) large multi-vesicular liposome hydrogel loaded with bupivacaine, with slow release and improved safety and efficacy demonstrated in first-in-human clinical study phase I.